Practical guidance for the in‐hospital management of PWH published in Haemophilia13 de mayo de 2020
Cédric Hermans ofrece valiosa orientación en Haemophilia6 de mayo de 2020
WFH Humanitarian Aid letter regarding home treatment29 de abril de 2020
New COVID‐19 pandemic article published in Haemophilia22 de abril de 2020
Webinario ofrece información actualizada sobre el impacto del COVID-19 en la comunidad 14 de abril de 2020
Carta a los países receptores de ayuda humanitaria de la FMH 8 de abril de 2020
Mensaje del presidente de la FMH y del director ejecutivo de la FMH 7 de abril de 2020
Haemophilia - makes published articles on COVID-19 free-to-access
WFH signs on to APLUS Statement on FDA Policy Changes Related to Blood and Plasma Donation 2 de abril de 2020
Riesgos específicos del COVID-19 para la comunidad de trastornos de la coagulación 2 de abril de 2020
Recomendaciones prácticas para personas con hemofilia 21 de marzo de 2020
Declaración de la FMH: Actualización sobre el COVID-19 4 de marzo de 2020
Declaración de la FMH sobre el brote de Nuevo Coronavirus (2019-nCoV) 3 de febrero de 2020
Novo Nordisk: To all physicians, haematologists, and other healthcare professionals 15 de mayo de 2020
Summary of responses, 11 May 2020
Response letter: Pfizer, 3 May 2020
Response letter: Apcintex, 10 April 2020
Response letter: Sanofi, 9 April 2020
Response letter: Roche, 9 April 2020
Takeda: Follow-up statement relating to SARS-CoV-2 – COVID-19 21 de mayo de 2020
BioMarin - Update for Global Hemophilia Associations - Impact of the COVID-19 pandemic 17 de abril de 2020
Sobi: COVID-19 Crisis Statement 14 de abril de 2020
CSL Behring’s Global Role in Battling COVID-19 10 de abril de 2020
Octapharma acts to accelerate development of COVID-19 plasma therapies 6 de abril de 2020
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy 6 de abril de 2020
How Pfizer is responding – Our Commitment to Support Continued Health and Safety 26 de marzo de 2020
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19 25 de marzo de 2020
Takeda: Follow-up statement concerning the impact of SARS-CoV-2 on the supply of treatment for persons with hemophilia and von Willebrand disease 23 de marzo 2020
Roche: Update on Hemlibra supply amid 2019-nCoV (novel coronavirus) 20 de marzo de 2020
Precision BioLogic’s COVID-19 Update 20 de marzo de 2020
Sanofi: Our Response to COVID-19 10 de marzo de 2020